Products for Research Use Only
RegisterLogin

Tezacaftor-d6

CAT: 0804-HY-15448S1Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-15448S1Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Tezacaftor-d6 (VX-661-d6) is deuterium labeled Tezacaftor. Tezacaftor (VX-661) is a F508del CFTR corrector. It helps CFTR protein reach the cell surface. However, Ivacaftor (VX-770, HY-13017), a CFTR potentiator, helps to prolong the opening time of cell surface CFTR protein channels. Tezacaftor combining with Ivacaftor, shows potent efficacy against cystic fibrosis and diseases with homozygous for the CFTR Phe508del mutation. Moreover, Elexacaftor (VX-445, HY-111772) is also a CFTR corrector. Elexacaftor-Tezacaftor-Ivacaftor aims at with cystic fibrosis (CF) with at least one Phe508del mutation, often avoids the indication for lung transplantation[1][2][3][4].
CAS Number
1961280-94-3
Product Name Alternative
VX-661-d6
UNSPSC
12352005
Target
CFTR; Isotope-Labeled Compounds
Related Pathways
Membrane Transporter/Ion Channel; Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
FC1=C(NC(C2(CC2)C3=CC=C4OC(OC4=C3)(F)F)=O)C=C5C(N(C[C@H](CO)O)C(C(C([2H])([2H])[2H])(CO)C([2H])([2H])[2H])=C5)=C1
Molecular Formula
C26H21D6F3N2O6
Molecular Weight
526.53
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Treatment with VX-661 and Ivacaftor in a Phase 2 Study Resulted in Statistically Significant Improvements in Lung Function in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation. April 18, 2013|[3]Taylor-Cousar JL, et al. Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. N Engl J Med. 2017 Nov 23;377 (21) :2013-2023. |[4]Burgel PR, et al. Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease. Am J Respir Crit Care Med. 2021 Jul 1;204 (1) :64-73. |[5]Huang Y, et al. Elexacaftor/Tezacaftor/Ivacaftor Improved Clinical Outcomes in a Patient with N1303K-CFTR Based on In Vitro Experimental Evidence. Am J Respir Crit Care Med. 2021 Nov 15;204 (10) :1231-1235.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Related Products

CatalogName
HY-15448-01Tezacaftor
HY-15448R-01Tezacaftor (Standard)
HY-15448STezacaftor-d4
HY-15448A-01(Rac) -Tezacaftor
HY-77932SDibenzyloxy Tezacaftor-d4
HY-110225-01Levetiracetam-d6 (ring-d6)
HY-N0893STetrahydrocurcumin-d6
HY-W750155Tetramethrin-d6
HY-W744578Taurolidine-d6
HY-W744275Tipelukast-d6

Alternative Products

CatalogName
CS-EO-02586Tezacaftor d6
TRC-T321510-10MGTezacaftor
T75230-01(Rac) -Tezacaftor
TMIH-0568-01Tezacaftor-d4
JH72184Tezacaftor (VX661)
CS-O-35537Tezacaftor Enantiomer
MBS5817155(Rac)-Tezacaftor
90036926Tezacaftor VX661
AR-T04729-01(S) -Tezacaftor
TRC-T254370-50MGTezacaftor Metabolite M1

Popular Products